Skip to content

Study · Animal study (in vivo) · rat · 2010

9 results

Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.

Axel AM, Mikkelsen JD, Hansen HH

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology3 Mar 2010Cited by 37 (Europe PMC)

PMID20200509 (opens in a new tab)PMCIDPMC3055463 (opens in a new tab)DOI10.1038/npp.2010.16 (opens in a new tab)PepBankPUB-20200509
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In obese rats, tesofensine significantly lowered body weight compared with vehicle.

    In plain wordsIn obese rats, tesofensine significantly lowered body weight compared with vehicle.

    Peptide
    Tesofensine
    Outcome
    DecreaseBody weight
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Vehicle-treated obese rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.0 mg/kg · subcutaneous · 16 daysAs given in this study (rat).

    Source sentences

    Summary
    DIO rats treated with tesofensine (2.0 mg/kg, s.c.) for 16 days showed significantly lower body weights than vehicle-treated DIO rats, being reflected by a marked hypophagic response.
    1 context sentence
    Summary · context
    Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In obese rats, tesofensine produced marked food intake suppression compared with vehicle.

    In plain wordsIn obese rats, tesofensine produced marked food intake suppression compared with vehicle.

    Peptide
    Tesofensine
    Outcome
    DecreaseFood intake during repeated treatment
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Vehicle-treated obese rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.0 mg/kg · subcutaneous · 16 daysAs given in this study (rat).

    Source sentences

    Summary
    DIO rats treated with tesofensine (2.0 mg/kg, s.c.) for 16 days showed significantly lower body weights than vehicle-treated DIO rats, being reflected by a marked hypophagic response.
    1 context sentence
    Summary · context
    Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In obese rats, tesofensine reduced food intake dose-dependently, with an ED(50) of 1.3 mg/kg.

    In plain wordsIn obese rats, tesofensine reduced food intake more at higher doses.

    Peptide
    Tesofensine
    Outcome
    DecreaseAcute food intake suppression
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.5-3.0 mg/kg · subcutaneous · 12-hour nocturnal testAs given in this study (rat).

    Measurements

    ED50
    1.3 mg/kg
    food intake suppression

    Source sentences

    Summary
    Tesofensine (0.5-3.0 mg/kg, s.c.) induced a dose-dependent and marked decline in food intake with an ED(50) of 1.3 mg/kg.
    2 context sentences
    Summary · context
    Using an automatized food intake monitoring system during a 12 h nocturnal test period, tesofensine-induced hypophagia was investigated further by studying the acute interaction of a variety of monoamine receptor antagonists with tesofensine-induced hypophagia in the DIO rat.
    Summary · context
    Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine.

Studies that did not test the peptide alone6

In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tesofensine.

  1. 04AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Mechanism

    In obese rats, prazosin almost completely reversed tesofensine-induced food intake suppression compared with tesofensine alone.

    In plain wordsIn obese rats, prazosin almost completely reversed tesofensine-induced food intake suppression compared with tesofensine alone.

    Peptide
    Tesofensine
    Outcome
    IncreaseFood intake suppression with prazosin
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Tesofensine alone
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    The hypophagic response of tesofensine (1.5 mg/kg, s.c.) was almost completely reversed by co-administration of prazosin (1.0 mg/kg, alpha(1) adrenoceptor antagonist) and partially antagonized by co-administration of SCH23390 (0.03 mg/kg, DA D(1) receptor antagonist).
    1 context sentence
    Summary · context
    Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  2. 05AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Mechanism

    In obese rats, SCH23390 partially reversed tesofensine-induced food intake suppression compared with tesofensine alone.

    In plain wordsIn obese rats, SCH23390 partially reversed tesofensine-induced food intake suppression compared with tesofensine alone.

    Peptide
    Tesofensine
    Outcome
    IncreaseFood intake suppression with SCH23390
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Tesofensine alone
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    The hypophagic response of tesofensine (1.5 mg/kg, s.c.) was almost completely reversed by co-administration of prazosin (1.0 mg/kg, alpha(1) adrenoceptor antagonist) and partially antagonized by co-administration of SCH23390 (0.03 mg/kg, DA D(1) receptor antagonist).
    1 context sentence
    Summary · context
    Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  3. 06AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Mechanism

    In obese rats, RX821002 did not affect tesofensine-induced food intake suppression compared with tesofensine alone.

    In plain wordsIn obese rats, RX821002 did not affect tesofensine-induced food intake suppression compared with tesofensine alone.

    Peptide
    Tesofensine
    Outcome
    No significant changeFood intake suppression with RX821002
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Tesofensine alone
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    In contrast, tesofensine-induced hypophagia was not affected by RX821002 (0.3 mg/kg, alpha(2) adrenoceptor antagonist), haloperidol (0.03 mg/kg, D(2) receptor antagonist), NGB2904 (0.1 mg/kg, D(3) receptor antagonist), or ritanserin (0.03 mg/kg, 5-HT(2A/C) receptor antagonist).
    1 context sentence
    Summary · context
    Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  4. 07AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Mechanism

    In obese rats, haloperidol did not affect tesofensine-induced food intake suppression compared with tesofensine alone.

    In plain wordsIn obese rats, haloperidol did not affect tesofensine-induced food intake suppression compared with tesofensine alone.

    Peptide
    Tesofensine
    Outcome
    No significant changeFood intake suppression with haloperidol
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Tesofensine alone
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    In contrast, tesofensine-induced hypophagia was not affected by RX821002 (0.3 mg/kg, alpha(2) adrenoceptor antagonist), haloperidol (0.03 mg/kg, D(2) receptor antagonist), NGB2904 (0.1 mg/kg, D(3) receptor antagonist), or ritanserin (0.03 mg/kg, 5-HT(2A/C) receptor antagonist).
    1 context sentence
    Summary · context
    Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  5. 08AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Mechanism

    In obese rats, NGB2904 did not affect tesofensine-induced food intake suppression compared with tesofensine alone.

    In plain wordsIn obese rats, NGB2904 did not affect tesofensine-induced food intake suppression compared with tesofensine alone.

    Peptide
    Tesofensine
    Outcome
    No significant changeFood intake suppression with NGB2904
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Tesofensine alone
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    In contrast, tesofensine-induced hypophagia was not affected by RX821002 (0.3 mg/kg, alpha(2) adrenoceptor antagonist), haloperidol (0.03 mg/kg, D(2) receptor antagonist), NGB2904 (0.1 mg/kg, D(3) receptor antagonist), or ritanserin (0.03 mg/kg, 5-HT(2A/C) receptor antagonist).
    1 context sentence
    Summary · context
    Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  6. 09AnimalNot a test of Tesofensine aloneAnimal study (in vivo)Mechanism

    In obese rats, ritanserin did not affect tesofensine-induced food intake suppression compared with tesofensine alone.

    In plain wordsIn obese rats, ritanserin did not affect tesofensine-induced food intake suppression compared with tesofensine alone.

    Peptide
    Tesofensine
    Outcome
    No significant changeFood intake suppression with ritanserin
    Study

    ratn: not reported in source

    Diet-induced obese rats
    Comparator
    Tesofensine alone
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    In contrast, tesofensine-induced hypophagia was not affected by RX821002 (0.3 mg/kg, alpha(2) adrenoceptor antagonist), haloperidol (0.03 mg/kg, D(2) receptor antagonist), NGB2904 (0.1 mg/kg, D(3) receptor antagonist), or ritanserin (0.03 mg/kg, 5-HT(2A/C) receptor antagonist).
    1 context sentence
    Summary · context
    Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine.

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.